MULTIPL demonstrated robust prognostic performance in external validation, identified a subgroup enriched for benefit from GNP, and enabled discovery and validation of prognostic biomarkers in metastatic PDAC, underscoring the value of the PASS-01 Challenge.
Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....
W. Quan, D. Henault, S. M. Hasnain et al.· Cancer Research· 0 citations
Neoadjuvant chemoradiotherapy (nCRT) is standard treatment for locally advanced rectal cancer (LARC), but responses vary substantially. We developed Fragmentia-AI Response, a machine learning model that uses cell-free DNA (cfDNA) fragment features to predict pathological response and recurrence risk without relying on...
Kun Miao, S. Wang, Guo-Feng Sun et al.· The journal of liquid biopsy· 0 citations
Survival research in pancreatic ductal adenocarcinoma (PDAC) is limited by the scarcity of datasets linking whole-slide histology with clinical, molecular, and long-term outcome data. We present a retrospective single-centre cohort of 302 patients who underwent PDAC resection at University Medical Center Gottingen. The...
Anh-Tien Nguyen, Mawuko Tettey, J. M. Metsch et al.· 0 citations
Accurately predicting the risk of early liver metastases (ELM) and identifying patients who are most likely to benefit from neoadjuvant therapy (NAT) are critical for pancreatic ductal adenocarcinoma (PDAC). Here, we develop a Mamba-based predictive model that integrates imaging features from both the primary pancreati...
Ben Zhao, Zhi-Fang Gong, W. Xiao et al.· Nature Communications· 0 citations
Breast cancer patients receiving neoadjuvant treatment may benefit from a presurgical assessment of complete response to avoid unnecessary surgeries. We aimed to develop a machine learning model that predicts pathological complete response (pCR) based on results from different image modalities as well as tumor and pati...
Eva Reisig, Lie Cai, Maria Müller et al.· BMC Cancer· 0 citations
A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.
Jungkyu Park, D. Biswas, J. Cappadona et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.